StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) in a report released on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Other equities analysts have also recently issued research reports about the company. Zacks Investment Research cut Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 19th. Brookline Capital Acquisition lowered their target price on Bellerophon Therapeutics from $26.00 to $19.00 in a research note on Monday, April 4th. Finally, Brookline Capital Management lowered their target price on Bellerophon Therapeutics from $26.00 to $19.00 in a research note on Monday, April 4th.

Shares of BLPH opened at $2.22 on Tuesday. The business’s fifty day moving average price is $2.17 and its 200 day moving average price is $2.80. Bellerophon Therapeutics has a 12-month low of $1.77 and a 12-month high of $5.95. The stock has a market capitalization of $21.20 million, a PE ratio of -1.18 and a beta of -0.54.

Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) last posted its earnings results on Thursday, March 31st. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.15. Sell-side analysts predict that Bellerophon Therapeutics will post -2.16 EPS for the current year.

An institutional investor recently bought a new position in Bellerophon Therapeutics stock. Millennium Management LLC acquired a new stake in shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 12,243 shares of the biotechnology company’s stock, valued at approximately $59,000. Millennium Management LLC owned 0.13% of Bellerophon Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 12.20% of the company’s stock.

About Bellerophon Therapeutics (Get Rating)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Featured Articles